28 reports

Its products include in-vitro diagnostic (IVD) makers, reagents, microtiter plate ELISA testing devices, turbidimetric reagents, rapid testing and bioblot assay products, and HIV and HCV confirmatory devices.

  • Immunotherapy
  • Medical Biotechnology
  • Spain
  • United States
  • Biokit S.A.
  • 2.5.1 PATHOPHYSIOLOGY

As such, confirmatory immunoblot tests are administered to patients who test positively for HCV infection, and patients who test negatively but are at a high risk of having a false-negative result are tested again.

  • Immunotherapy
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

HCV VIRAL LOAD TEST - PROTEASE INHIBITOR (RG##) HCV VIRAL LOAD TEST - PROTEASE INHIBITOR (RG##) PRODUCT OVERVIEW HCV VIRAL LOAD TEST - PROTEASE INHIBITOR (RG##) - PRODUCT STATUS Market Category Developed By Pipeline Territory Highest Stage

  • Anti-Infective
  • Antiviral
  • Immunotherapy
  • Targeted Therapy
  • Roche Group

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Immunotherapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) - PIPELINE BY LIVZON PHARMACEUTICAL GROUP INC, H1 2018

Livzon offers diagnostic kits such as BV quick-test kit, anti-HCV rapid test, mycoplasma ICS kit, anti-HAV IgM ELISA kit, anti-TOXO IgG ELISA and HBsAg ELISA kit.

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Company Operations
  • Product Initiative
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2018
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H1 2018

Livzon offers diagnostic kits such as BV quick-test kit, anti-HCV rapid test, mycoplasma ICS kit, anti-HAV IgM ELISA kit, anti-TOXO IgG ELISA and HBsAg ELISA kit.

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Novartis AG

Harvoni was approved for pediatric patients with genotype ##, ##, ## or ## HCV infection.

  • HIV AIDS
  • Immunotherapy
  • Pharmaceutical
  • United States
  • Gilead Sciences, Inc.
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H2 2018
  • golimumab

Livzon offers diagnostic kits such as BV quick-test kit, anti-HCV rapid test, anti-HAV IgM ELISA kit, anti-TOXO IgG ELISA and HBsAg ELISA kit.

  • Immunotherapy
  • Medical Biotechnology
  • Musculoskeletal Disorder
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

Further, while HCV genotypes ## and ## make up the majority of HCV infections, other trials have shown similarly positive results with the short eight-week course when testing glecaprevir-pibrentasvir in genotypes ##, ##, ## and ##.

  • Antiviral
  • Hepatitis
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company
  • POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) - PIPELINE BY LIVZON PHARMACEUTICAL GROUP INC, H2 2016

Livzon provides diagnostic kits such as BV quick-test kit, anti-HCV rapid test, mycoplasma ICS kit, anti-HAV IgM ELISA kit, anti-TOXO IgG ELISA, and HBsAg ELISA kit.

  • Autoimmune Disease
  • Immunotherapy
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Coherus BioSciences, Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Cell Therapy
  • Hospital
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company

IT IS A HCV INFECTIVITY INHIBITOR ## (HCV II-##).

  • Hepatitis
  • Immunotherapy
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Endometrial Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

In June 2014, PRISM Pharma Co. Ltd registered an open label, single arm, dose escalation Phase ## trial of PRI-## in patients with HCV-induced cirrhosis.

  • Hepatitis
  • Immunotherapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Hospital
  • Immunotherapy
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Endometrial Cancer
  • Immunotherapy
  • North America
  • United States
  • Merck & Co., Inc.

The trial included ## HCC patients who were enrolled into one of three treatment arms depending on whether or not they were infected with HCV or HBV.

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative

The trial included ## HCC patients who were enrolled into one of three treatment arms depending on whether or not they were infected with HCV or HBV.

  • Cancer
  • Immunotherapy
  • United States
  • Company
  • Product Initiative

The trial included ## HCC patients who were enrolled into one of three treatment arms depending on whether or not they were infected with HCV or HBV.

  • Immunotherapy
  • Oncology
  • United States
  • Company
  • Product Initiative

THE PRIMARY OUTCOME MEASURES OF THIS STUDY ARE TO ASSESS THE ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, LABORATORY RESULTS (HEMATOLOGY, SERUM BLOOD CHEMISTRY, HEPATITIS TESTS, STANDARD URINALYSIS DIPSTICK ASSESSMENT, COAGULATION STUDIES)OR ASSESSMENT OF THE INCIDENCE OF PNEUMONITIS.

  • Immunotherapy
  • Lymphoma
  • North America
  • United States
  • Product Initiative

One study passed its predefined statistical test in triple negative breast cancer.

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative

The trial included ## HCC patients who were enrolled into one of three treatment arms depending on whether or not they were infected with HCV or HBV.

  • Immunotherapy
  • Prostate Cancer
  • United States
  • Company
  • Company Operations

The primary outcome measures are safety, AUC, change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v##. ## for high pure system and proportion of patients with unquantifiable/ undetectable HCV RNA during the study.

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States